elcome back to part two of STAT’s conversation with Leerink Partners health care analysts Geoff Porges, Seamus Fernandez, and Paul Matteis.

In this edited excerpt, the analysts share their opinions of Trump’s FDA and how new Commissioner Scott Gottlieb could impact drug pricing. They dish on the best management teams in biotech and pharma and point out some under-the-radar industry trends that warrant closer watch.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.